At its September meeting, Europe’s Pharmacovigilance Risk Assessment Committee (PRAC) discussed a direct healthcare professional communication that will warn clinicians about the risk for severe ...
Kedrion Biopharma announced today that it has received FDA approval for QIVIGY immune globulin intravenous (human)-kthm 10% ...
The U.S. has seen a dramatic increase in a dangerous type of drug-resistant bacteria. And the Centers for Disease Control and ...
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...
The FDA has approved Qivigy (immune globulin intravenous, human-kthm) 10% solution for the treatment of adults with primary humoral immunodeficiency.
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and ...
Dr. Singhi speaks with us about the importance of biomarker testing and what you need to know to get the best lung cancer ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the ...
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to ...
Absci is developing ABS-101, an anti-TL1A antibody with potential in ulcerative colitis, Crohn's disease, and other ...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year ...
Spyre's innovative ulcerative colitis antibody therapies, phase 2 trial progress, and strong cash position to drive drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback